文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

氟康唑联用直接口服抗凝药的出血风险影响

Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk.
PubMed 文献 · Pharmacotherapy · 2022-11-04

一项回顾性队列研究纳入216例住院成人患者,比较直接口服抗凝药(DOAC)联用或不联用氟康唑的30天出血复合终点。联用组出血事件数值更高(32% vs 19%,p=0.03),但校正混杂因素后无统计学显著性(校正OR 1.71,95%CI 0.85-3.40)。

要点

  • DOAC联用氟康唑30天出血率数值更高,但校正后无显著差异。
  • 研究仅纳入氟康唑日剂量≥400mg且DOAC剂量符合房颤或静脉血栓栓塞适应证者。
  • 结果提示临床决策时需结合患者个体出血风险综合评估。

核心结论

  • 住院患者DOAC联用氟康唑在控制混杂变量后未显著增加30天出血风险。

研究设计与样本

  • 回顾性队列研究,纳入2016年10月1日至2021年9月30日期间俄亥俄州立大学Wexner医疗中心住院的18-89岁患者,共216例,按DOAC种类匹配,联用氟康唑组与单用DOAC组各108例。

主要发现

  • 联用氟康唑组30天出血事件为35/108(32%),单用DOAC组为21/108(19%),p=0.03。
  • 校正血红蛋白和联用卡维地洛后,校正OR为1.71(95%CI 0.85-3.40),无统计学显著性。

关键数值与推荐

  • 纳入标准:住院成人年龄18-89岁,接受阿哌沙班或利伐沙班治疗,DOAC或联用氟康唑最短疗程48小时。
  • 排除标准:氟康唑日剂量<400mg,或DOAC剂量超出房颤或静脉血栓栓塞治疗/预防推荐范围。
  • 主要终点为30天内大出血、临床相关非大出血和轻微出血的复合终点。

临床怎么用

  • 对于住院患者需联用氟康唑(日剂量≥400mg)与阿哌沙班或利伐沙班时,可参考本研究结果评估出血风险,但需个体化考虑患者血红蛋白水平及是否联用卡维地洛等混杂因素。

局限性

  • 回顾性设计可能残余混杂,样本量较小(216例),仅纳入阿哌沙班和利伐沙班,氟康唑剂量限制在≥400mg/日,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The aim of this study was to evaluate the effect on bleeding risk when fluconazole is administered concomitantly with direct oral anticoagulants (DOACs). DESIGN: This was a retrospective cohort study including hospitalized adult patients prescribed a DOAC with or without fluconazole. SETTING: The Ohio State University Wexner Medical Center, a tertiary care academic medical center with more than 1800 beds. PATIENTS: Hospitalized patients ages 18-89 years who received apixaban or rivaroxaban with or without fluconazole from October 1, 2016, to September 30, 2021, were included. The minimum duration of DOAC or DOAC with fluconazole therapy was 48 h. Patients were excluded if they received fluconazole <400 mg daily or a DOAC at doses outside those recommended for atrial fibrillation or venous thromboembolism treatment or prophylaxis. Patients were matched based on DOAC received. INTERVENTION: Patients who received a DOAC with fluconazole were compared with those receiving a DOAC alone. The primary outcome was a composite of major, clinically relevant nonmajor, and minor bleeding events at 30 days. MEASUREMENTS AND MAIN RESULTS: There were 216 patients included, 108 in the DOAC with fluconazole group and 108 in the DOAC alone group. More patients in the DOAC with fluconazole group experienced bleeding at 30 days compared with the DOAC alone group [35/108 (32%) vs. 21/108 (19%), respectively; p = 0.03]; however, after adjusting for proven confounding variables (hemoglobin and concomitant carvedilol) this was found not to be statistically significant [adjusted odds ratio 1.71, 95% confidence interval 0.85-3.40]. CONCLUSIONS: Patients receiving a DOAC with fluconazole were not at significantly increased risk for bleeding at 30 days compared with those receiving a DOAC alone after controlling for confounding variables. As an increasing number of patients are prescribed DOACs, the results of this study may inform clinical decision-making on the safety of concomitant DOAC and fluconazole use.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Cid A, Smetana ME, Hebert C, et al. Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk. Pharmacotherapy. 2022. PMID: 36271717. doi:10.1002/phar.2738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。